Bronchus- and nasal-associated lymphoid tissues.

PubWeight™: 1.42‹?› | Rank: Top 5%

🔗 View Article (PMID 16048540)

Published in Immunol Rev on August 01, 2005

Authors

John Bienenstock1, Mark R McDermott

Author Affiliations

1: McMaster University, Hamilton, ON, Canada.

Articles citing this

Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest (2006) 2.56

Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectives. Environ Health Perspect (2010) 1.58

Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol (2009) 1.55

Loss of receptor on tuberculin-reactive T-cells marks active pulmonary tuberculosis. PLoS One (2007) 1.39

Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J Immunol (2010) 1.26

Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol (2009) 1.13

Reovirus preferentially infects the basolateral surface and is released from the apical surface of polarized human respiratory epithelial cells. J Infect Dis (2008) 1.02

The tonsils revisited: review of the anatomical localization and histological characteristics of the tonsils of domestic and laboratory animals. Clin Dev Immunol (2011) 0.98

NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant. J Immunol (2010) 0.97

Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J (2010) 0.93

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. Vaccine (2010) 0.92

Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One (2011) 0.91

Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols. Infect Immun (2009) 0.89

B-lymphocyte lineage cells and the respiratory system. J Allergy Clin Immunol (2013) 0.89

The suckling rat as a model for immunonutrition studies in early life. Clin Dev Immunol (2012) 0.88

In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect Immun (2006) 0.87

Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia. PLoS One (2010) 0.86

Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr HIV Res (2008) 0.85

Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung. Respir Res (2009) 0.85

Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation. Am J Pathol (2014) 0.84

Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100. PLoS One (2012) 0.83

Initiation of acquired immunity in the lungs of mice lacking lymph nodes after infection with aerosolized Mycobacterium tuberculosis. Am J Pathol (2009) 0.83

Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue. Clin Vaccine Immunol (2011) 0.83

B cells are not essential for Lactobacillus-mediated protection against lethal pneumovirus infection. J Immunol (2014) 0.83

Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery. Clin Vaccine Immunol (2013) 0.81

Coincidence of different structures of mucosa-associated lymphoid tissue (MALT) in the respiratory tract of children: no indications for enhanced mucosal immunostimulation in sudden infant death syndrome (SIDS). Clin Exp Immunol (2006) 0.80

Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. Int Immunol (2011) 0.80

Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract. Inmunologia (2007) 0.80

Mucosal vaccine delivery: Current state and a pediatric perspective. J Control Release (2016) 0.80

Follicular dendritic cell secreted protein FDC-SP controls IgA production. Mucosal Immunol (2014) 0.79

Pathogen-specific circulating plasmablasts in patients with pneumonia. PLoS One (2012) 0.78

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics (2014) 0.78

Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines (Basel) (2014) 0.77

Pharyngeal microflora disruption by antibiotics promotes airway hyperresponsiveness after respiratory syncytial virus infection. PLoS One (2012) 0.77

B cell response to herpesvirus infection of the olfactory neuroepithelium. J Virol (2014) 0.77

Haemophilus influenzae and smoking-related obstructive airways disease. Int J Chron Obstruct Pulmon Dis (2011) 0.77

Primary cystic lung light chain deposition disease: a clinicopathologic entity derived from unmutated B cells with a stereotyped IGHV4-34/IGKV1 receptor. Blood (2008) 0.76

Challenges in mucosal HIV vaccine development: lessons from non-human primate models. Viruses (2014) 0.76

A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma. J Thorac Dis (2017) 0.75

Reconstruction is not renovation - the role of remodeling in asthma. J Asthma Allergy (2009) 0.75

Impaired sense of smell and altered olfactory system in RAG-1(-∕-) immunodeficient mice. Front Neurosci (2015) 0.75

Bioengineering of Artificial Lymphoid Organs. Acta Naturae (2016) 0.75

Probing local innate immune responses after mucosal immunisation. J Immune Based Ther Vaccines (2010) 0.75

Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines (Basel) (2016) 0.75

Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation. Vaccines (Basel) (2017) 0.75